AstraZeneca appoints new chief financial officer

AstraZeneca has announced the appointment of Marc Dunoyer as its new chief financial officer, effective as of November 1st 2013.

Mr Dunoyer – the company's current executive vice-president for global portfolio and product strategy – will be joining AstraZeneca's board as an executive director and will be reporting directly to chief executive officer Pascal Soriot in his new role.

He has been appointed as the successor to Simon Lowth, who is leaving AstraZeneca today (October 31st 2013).

The new chief financial officer joined the organisation from GlaxoSmithKline in June 2013 and is qualified as an accountant, with his subsequent career in pharmaceuticals giving him extensive experience of various industry issues and functions.

Mr Soriot said Mr Dunoyer possesses a "rare blend of financial, business and science experience that will be critical in this role in the coming years as we focus on returning AstraZeneca to growth and achieving scientific leadership".

The company also announced its financial results for the third quarter of 2013 today, reporting a revenue total of $6.25 billion (3.9 billion pounds).